143 related articles for article (PubMed ID: 37858585)
21. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
22. Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
Goldstein N; Bockstal V; Bart S; Luhn K; Robinson C; Gaddah A; Callendret B; Douoguih M
J Infect Dis; 2022 Sep; 226(4):595-607. PubMed ID: 32939546
[TBL] [Abstract][Full Text] [Related]
23. Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children.
Ishola D;
Clin Infect Dis; 2022 Oct; 75(9):1585-1593. PubMed ID: 35640636
[TBL] [Abstract][Full Text] [Related]
24. Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.
Badio M; Lhomme E; Kieh M; Beavogui AH; Kennedy SB; Doumbia S; Leigh B; Sow SO; Diallo A; Fusco D; Kirchoff M; Termote M; Vatrinet R; Wentworth D; Esperou H; Lane HC; Pierson J; Watson-Jones D; Roy C; D'Ortenzio E; Greenwood B; Chêne G; Richert L; Neaton JD; Yazdanpanah Y;
Trials; 2021 Jan; 22(1):86. PubMed ID: 33485369
[TBL] [Abstract][Full Text] [Related]
25. Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
Nyombayire J; Ingabire R; Magod B; Mazzei A; Mazarati JB; Noben J; Katwere M; Parker R; Nsanzimana S; Wall KM; Sayinzoga F; Tichacek A; Robinson C; Hammoud N; Priddy F; Allen S; Karita E
J Infect Dis; 2023 Jan; 227(2):268-277. PubMed ID: 35776140
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.
Manno D; Patterson C; Drammeh A; Tetteh K; Kroma MT; Otieno GT; Lawal BJ; Soremekun S; Ayieko P; Gaddah A; Kamara AB; Baiden F; Afolabi MO; Tindanbil D; Owusu-Kyei K; Ishola D; Deen GF; Keshinro B; Njie Y; Samai M; Lowe B; Robinson C; Leigh B; Drakeley C; Greenwood B; Watson-Jones D
Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631885
[TBL] [Abstract][Full Text] [Related]
27. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
[TBL] [Abstract][Full Text] [Related]
28. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Mbaye KD; Thiongane A; Ndiaye BP; Ndour CT; Mboup S; Keshinro B; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Gobert P; Hogrefe WR; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):719-730. PubMed ID: 32199492
[TBL] [Abstract][Full Text] [Related]
29. Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.
Karita E; Nyombayire J; Ingabire R; Mazzei A; Sharkey T; Mukamuyango J; Allen S; Tichacek A; Parker R; Priddy F; Sayinzoga F; Nsanzimana S; Robinson C; Katwere M; Anumendem D; Leyssen M; Schaefer M; Wall KM
Trials; 2022 Jun; 23(1):513. PubMed ID: 35725488
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
Henao-Restrepo AM; Camacho A; Longini IM; Watson CH; Edmunds WJ; Egger M; Carroll MW; Dean NE; Diatta I; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Gsell PS; Hossmann S; Watle SV; Kondé MK; Kéïta S; Kone S; Kuisma E; Levine MM; Mandal S; Mauget T; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Røttingen JA; Kieny MP
Lancet; 2017 Feb; 389(10068):505-518. PubMed ID: 28017403
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
[TBL] [Abstract][Full Text] [Related]
32. A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks.
Shukarev G; Callendret B; Luhn K; Douoguih M;
Hum Vaccin Immunother; 2017 Feb; 13(2):266-270. PubMed ID: 27925844
[TBL] [Abstract][Full Text] [Related]
33. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD; Sow SO; Ndiaye BP; Mbaye KD; Thiongane A; Ndour CT; Mboup S; Ake JA; Keshinro B; Akintunde GA; Kinge TN; Vernet G; Bigna JJ; Oguche S; Koram KA; Asante KP; Hogrefe WR; Günther S; Naficy A; De Ryck I; Debois M; Bourguignon P; Jongert E; Ballou WR; Koutsoukos M; Roman F;
Lancet Infect Dis; 2020 Jun; 20(6):707-718. PubMed ID: 32199491
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
De Santis O; Audran R; Pothin E; Warpelin-Decrausaz L; Vallotton L; Wuerzner G; Cochet C; Estoppey D; Steiner-Monard V; Lonchampt S; Thierry AC; Mayor C; Bailer RT; Mbaya OT; Zhou Y; Ploquin A; Sullivan NJ; Graham BS; Roman F; De Ryck I; Ballou WR; Kieny MP; Moorthy V; Spertini F; Genton B
Lancet Infect Dis; 2016 Mar; 16(3):311-20. PubMed ID: 26725450
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
[TBL] [Abstract][Full Text] [Related]
36. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG
PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239
[TBL] [Abstract][Full Text] [Related]
38. Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo.
Blengio F; Hocini H; Richert L; Lefebvre C; Durand M; Hejblum B; Tisserand P; McLean C; Luhn K; Thiebaut R; Levy Y
Cell Rep; 2023 Sep; 42(9):113101. PubMed ID: 37691146
[TBL] [Abstract][Full Text] [Related]
39. Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
Mwesigwa B; Sawe F; Oyieko J; Mwakisisile J; Viegas E; Akintunde GA; Kosgei J; Kokogho A; Ntinginya N; Jani I; Shukarev G; Hooper JW; Kwilas SA; Ward LA; Rusnak J; Bounds C; Overman R; Badorrek CS; Eller LA; Eller MA; Polyak CS; Moodley A; Tran CL; Costanzo MC; Leggat DJ; Paquin-Proulx D; Naluyima P; Nkafu Anumendem D; Gaddah A; Luhn K; Hendriks J; McLean C; Douoguih M; Kibuuka H; Robb ML; Robinson C; Ake JA
Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38657084
[TBL] [Abstract][Full Text] [Related]
40. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.
Huttner A; Agnandji ST; Combescure C; Fernandes JF; Bache EB; Kabwende L; Ndungu FM; Brosnahan J; Monath TP; Lemaître B; Grillet S; Botto M; Engler O; Portmann J; Siegrist D; Bejon P; Silvera P; Kremsner P; Siegrist CA; ; ;
Lancet Infect Dis; 2018 Jul; 18(7):738-748. PubMed ID: 29627147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
